iBio, AstralBio unveil obesity program with amylin receptor agonist antibody

iBio (IBIO) announced preclinical data in which an engineered amylin receptor agonist antibody reduced acute food intake in a mouse model of obesity by 60%, equivalent to the reduction in food intake from a clinically advanced dual amylin and calcitonin receptor agonist, DACRA, peptide. The effect on food intake was monitored over various time points in this side-by-side study with the amylin agonist iBio discovered and a DACRA peptide. The study marks the third target to emerge from iBio’s partnership with AstralBio. The successful iBio-AstralBio collaboration now includes multiple novel engineered antibody agonists with a wide range of profiles targeting the amylin receptor, a heterodimeric G protein-coupled receptor.